ClinicalTrials.gg
CompletedNCT02262780Updated Dec 8, 2023

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

A Phase 1 interventional study of Low dose of telmisartan and High dose of telmisartan in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 years 10 months after the study started (first participant enrolled Dec 2003, registered Oct 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

Group 1:

To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T40/H12.5 and T80/H12.5)

Group 2:

To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T80/H12.5 x 7 days)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males according to the following criteria: No finding deviating of clinical relevance and no evidence of a concomitant disease based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR), body temperature), 12-lead , clinical laboratory tests
  • Age ≥20 and Age ≤35 years
  • (BMI) ≥17.6 and BMI ≤26.4 kg/m2
  • Signed and dated written prior to admission to the study in accordance with "Good Clinical Practice (GCP)"

Exclusion criteria

Exclusion Criteria:

  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • Chronic or relevant acute infections
  • Any laboratory value outside the reference range that is of clinical relevance
  • Positive result for surface (HBs) antigen, anti virus (HCV) antibodies, Syphilitic test or test
  • Surgery of gastrointestinal tract (except appendectomy)
  • History of relevant orthostatic hypotension (mean standing SBP varies by ≥ 20 mmHg from mean supine systolic blood pressure (SBP) and/or mean standing diastolic blood pressure (DBP) varies by ≥ 10 mmHg from mean supine DBP), fainting spells or blackouts.
  • History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)
  • History of serious renal dysfunction
  • History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney
  • History of cerebrovascular disorder
  • History of hyperkalemia
  • Known to any component of the formulation; known hypersensitivity to any other angiotensin II receptor antagonist; known hypersensitivity to sulfonamides or sulphonamide-derived drugs (e.g. thiazides)
  • History of impaired glucose tolerance
  • History of hypokalemia
  • History of hyperuricemia
  • Salt restriction therapy
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days prior to administration or during the trial
  • Participation in another trial with an drug within four months or 6 half-lives of the investigational drug, whichever is longer, prior to administration or during the trial
  • Smoker (more than 20 cigarettes /day)
  • Alcohol abuse
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within seven days prior to administration)
  • Intake of alcohol within two days prior to administration
  • Inability to comply with dietary regimen of study centre
  • Inability to comply with smoking cessation during hospitalization
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Single low dose Telmisartan with HCTZ

    Drug: Low dose of telmisartan · Drug: HCTZ

  • Experimental
    Single high dose Telmisartan with HCTZ

    Drug: High dose of telmisartan · Drug: HCTZ

  • Experimental
    Multiple high dose Telmisartan with HCTZ

    Drug: High dose of telmisartan · Drug: HCTZ

Interventions

  • DrugLow dose of telmisartan
  • DrugHigh dose of telmisartan
  • DrugHCTZ
06

What researchers measure

Primary outcomes

  1. Number of patients with clinically relevant findings in physical examination

    Time frame: up to 10 days after last drug administration

  2. Number of patients with clinically relevant findings in vital signs

    blood pressure, pulse rate, body temperature

    Time frame: up to 10 days after last drug administration

  3. Number of patients with clinically relevant findings in 12-lead ECG

    Time frame: up to 10 days after last drug administration

  4. Number of patients with clinically relevant findings in clinical laboratory tests

    Time frame: up to 10 days after last drug administration

  5. Number of patients with adverse events

    Time frame: up to 10 days after last drug administration

  6. Global assessment of tolerability by the investigator

    verbal rating scale

    Time frame: up to 10 days after last drug administration

Secondary outcomes

  1. Maximum concentration of the analytes in plasma (Cmax)

    Time frame: Up to 96 hours after drug administration

  2. Area under the concentration time curve of the analytes in plasma (AUC)

    Time frame: Up to 96 hours after drug administration

  3. Time from dosing to maximum concentration of the analytes in plasma (tmax)

    Time frame: Up to 96 hours after drug administration

  4. Terminal rate constant of the analytes in plasma (λz)

    Time frame: Up to 96 hours after drug administration

  5. Terminal half-life of the analytes in plasma (t1/2)

    Time frame: Up to 96 hours after drug administration

  6. Mean residence time of the analytes in the body after po administration (MRTpo)

    Time frame: Up to 96 hours after drug administration

  7. Apparent clearance of the analytes in the plasma after extravascular administration (CL/F)

    Time frame: Up to 96 hours after drug administration

  8. Apparent volume of distribution of the analytes in plasma during the terminal phase λz following an extravascular dose (Vz/F)

    Time frame: Up to 96 hours after drug administration

  9. Amount of HCTZ that is eliminated in urine from the time interval t1 to t2 (Aet1-t2)

    Time frame: Up to 48 hours after drug administration

  10. Fraction of HCTZ excreted unchanged in urine from time point t1 to t2 (fet1-t2)

    Time frame: Up to 48 hours after drug administration

  11. Renal clearance of HCTZ in plasma from the time point t1 until the time point t2 (CLR, t1-t2)

    Time frame: Up to 48 hours after drug administration

  12. Minimum measured concentration of the analytes in plasma at steady state over a uniform dosing interval τ (Cmin,ss)

    Time frame: Up to 96 hours after drug administration

  13. Average concentration of the analytes in plasma at steady state (Cavg)

    Time frame: Up to 96 hours after drug administration

  14. Accumulation ratio of the analytes in plasma after multiple dose administration over a uniform dosing interval τ (RA)

    Time frame: Up to 96 hours after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2003 to primary completion in Feb 2004, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2014
First posted
Oct 13, 2014
StartActual
Dec 1, 2003
Primary completionActual
Feb 15, 2004
Last update
Dec 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02262780
Responsible party
Sponsor
First posted
Oct 13, 2014
Start date
Dec 1, 2003
Primary completion
Feb 15, 2004
Last update
Dec 8, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion